 LEEDS, England--BUSINESS WIRE--4D pharma plc AIM: DDD, NASDAQ: LBPS, a pharmaceutical company leading the development of Live Biotherapeutic products LBPs, a novel class of drug derived from the microbiome, today announces the completion of its target enrollment of 30 patients for Part A of its Phase III clinical trial of MRx-4DP0004 in patients with partly-controlled asthma. Following the completion of enrollment of Part A, 4D pharma expects to announce topline results from these patie 